Drug Trial Radar · NCT05734040
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
478
Actual
Start
May 10, 2023
Primary completion
Aug 10, 2023
Study completion Jan 15, 2024
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited; Mater Misericordiae Limited
- First posted
- Feb 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The present study OVX836-006 aims principally to: * Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e. as two separate concomitant injections into opposite arms; * Introduce an additional representative brand of Quadrivalent Inactivated Influenza Vaccines ; * Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the Hemagglutinin response; * Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the nucleoprotein response; * Evaluate the absolute vaccine efficacy of OVX836 compared to placebo in order to corroborate the efficacy signals previously detected in the OVX836 previous studies; * Evaluate the combined vaccine efficacy of OVX836 + Quadrivalent Inactivated Influenza Vaccines versus OVX836 + placebo, and versus double placebo.
Conditions
- Influenza
Interventions
OVX836 480µgBiological
One single administration intramuscularly at Day 1
Fluarix TetraBiological
One single administration intramuscularly at Day 1
Afluria QuadBiological
One single administration intramuscularly at Day 1
PlaceboBiological
One single administration intramuscularly at Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of seroconversion determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Inactivated Influenza Vaccines.Time frame: At Day 29 versus pre-injection baseline (Day 1)
- Proportion of subjects achieving a titer ≥1:40 at Day 29 determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Inactivated Influenza Vaccine.Time frame: At Day 29
- Number of Hemagglutination-Inhibition assay titers geometric mean ratios >2.5 for the four influenza strains contained in the Quadrivalent Inactivated Influenza Vaccines.Time frame: At Day 29 versus pre-injection baseline (Day 1)
- Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic signs and symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever)Time frame: During 7 days after vaccine administration
- Proportion of subjects reporting unsolicited Adverse EventsTime frame: During 29 days after vaccine administration
- Proportion of subjects reporting Serious Adverse EventsTime frame: During the whole study duration, 180 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
Emeritus Research Sydney
Sydney, New South Wales, Australia
Paratus Clinical Research Western Sydney
Sydney, New South Wales, Australia
Paratus Clinical Research Brisbane
Brisbane, Queensland, Australia
Mater Misericordiae Limited
Brisbane, Queensland, Australia
UniSC Clinical Trials Moreton Bay
Morayfield, Queensland, Australia
University of Sunshine Coast
Sippy Downs, Queensland, Australia
CMAX Fusion Clinical Research
Adelaide, South Australia, Australia
Emeritus
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.